Eli Lilly and Company operates in the Pharmaceutical preparations sector.
In addition to historical fundamental analyses, the complete report available to purchase compares Eli Lilly and Company with three other
companies in this sector in the United States:
AstraZeneca PLC
(2018
sales of $22.09 billion
of which 100%
was Pharmaceuticals),
Bristol-Myers Squibb Company
($22.56 billion
of which 100%
was BioPharmaceuticals), and
Teva Pharmaceutical Industries Limited
($18.85 billion
of which 49%
was North America).
Sales Analysis.
Eli Lilly and Company reported sales of $24.56 billion
for the
year ending
December of 2018.
This
represents
an
increase of 7.4%
versus 2017, when the company's sales were $22.87 billion.
This was the fourth straight year of sales growth at Eli Lilly and Company.
The sales level in 2018 was fairly close to the level five years ago: in 2013, Eli Lilly and Company had sales
of $23.11 billion.
Sales of Human Pharmaceutical Products-Immunology saw an increase
that was more than double the company's growth rate: sales were up
88.4% in 2018, from
$605.10 million to $1.14 billion.
Eli Lilly and Company also saw significant increases in sales in
Human Pharmaceutical Products - Endocrin (up 16.0% to $11.70 billion)
and
Human Pharmaceutical Products-Oncology (up 11.8% to $4.26 billion)
.
Not all segments of Eli Lilly and Company experienced an increase in sales in 2018:
sales of Human Pharmaceutical Products - Cardiova fell 21.5% to $2.25 billion.
Eli Lilly and Company also experienced decreases in sales in
Human Pharmaceutical Products -Neuroscie (down 16.1% to $1.82 billion)
and
Other Pharmaceuticals (down 2.5% to $235.30 million)
.